Corticosteroids for septic shock - A standard of care?

British Journal of Anaesthesia

Volumn 93, Issue 2, 2004, Pages 178-180

  Bloomfield, R ^a   Noble, David W ^a  

^a ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DROTRECOGIN; ETOMIDATE; FLUDROCORTISONE; HYDROCORTISONE; HYPERTENSIVE FACTOR; METYRAPONE;

ADRENAL SUPPRESSION; ARTIFICIAL VENTILATION; CLINICAL TRIAL; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DRUG MECHANISM; EDITORIAL; EVIDENCE BASED MEDICINE; HOSPITAL INFECTION; HUMAN; HYPERGLYCEMIA; IATROGENIC DISEASE; INFECTION; INTENSIVE CARE UNIT; METABOLIC BONE DISEASE; PRIORITY JOURNAL; PSYCHOSIS; RISK BENEFIT ANALYSIS; SEPTIC SHOCK; SIDE EFFECT; STATISTICAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 4344612737     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/aeh175     Document Type: Editorial

References (37)

1. Wenzel RP. Treating sepsis. N Engl J Med 2002; 347: 966-7
2. Annane D, Aegerter P, Jans-Guincestre MC, Guidet B. Current epidemiology of septic shock. The CUB-Réa Network. Am J Respir Crit Care Med 2003; 168: 165-72
3. Edbrooke DL, Hibbert CL, Kingsley JM, Smith S, Bright NM, Quinn M. The patient-related costs of care for sepsis patients in a United Kingdom adult general intensive care unit. Crit Care Med 1999; 27: 1760-7
4. Letarte J, Longo CJ, Pelletier J, Nabonne B, Fisher HN. Patient characteristics and costs of severe sepsis and septic shock in Quebec. J Crit Care 2002; 17: 39-49
5. Dinarello CA, Abraham E. Does blocking cytokines in sepsis work? Am J Respir Crit Care Med 2002; 166: 1156-7
6. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med 2003; 348: 138-50
7. The Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticosteroid therapy on mortality in patients with clinical signs of sepsis. N Engl J Med 1987; 317: 659-65
8. Bone RC, Fisher CJ, Clemmer TP, et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317: 653-8
9. Lefering R, Neugebauer EAM. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med 1995; 23: 1294-303
10. Cronin L, Cook DJ, Carlet J, et al. Corticosteroids treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med 1995; 23: 1430-9
11. Annane D, Bellissant E, Sebille V, et al. Impaired pressor sensitivity to norepinephrine in septic shock patients with and without impaired adrenal reserve. Br J Clin Pharmacol 1998; 46: 589-97
12. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998; 26: 645-50
13. Briegel J Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective randomized, double blind, single-center study. Crit Care Med 1999; 27: 723-32
14. Keh D, Boehnke T, Weber-Cartens S, et al. Immunologic and hemodynamic effects of 'low-dose' hydrocortisone in septic shock. A double-blind, randomized placebo-controlled crossover study. Am J Respir Crit Care Med 2003; 167: 512-20
15. Baue AE. The horror autotoxicus and multiple-organ failure. Arch Surg 1992; 127: 1451-62
16. Barnes PJ, Adcock IM. How do corticosteroids work in asthma? Ann Intern Med 2003; 139: 359-70
17. Annane D. Corticosteroids for septic shock. Crit Care Med 2001; 29: s117-20
18. McCombs CC, deShazo RD. Immune system disorders. In: Speight TM, Holford NHG, eds. Drug Treatment, 4th Edn. Chester: Adis International Ltd, 1997; 1304
19. De Jonghe B. Sharsar T, Lefaucheur JP, et al. Paresis acquired in the intensive care unit. JAMA 2002; 288: 2859-67
20. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996: 125: 605-13
21. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288: 862-71
22. Bernard G, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein c for severe sepsis. N Engl J Med 2001; 344: 699-709
23. Cooper MS, Stewart PM. Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003; 348: 727-34
24. Nasraway SA. The problems and challenges of immunotherapy in sepsis. Chest 2003; 123: 451-9s
25. Webster NR. Evidence based practice in intensive care - light on the horizon? Br J Anaesth 2001; 87: 377-9
26. Bourne RS, Webber SJ, Hutchison SP. Adrenal axis testing and corticosteroid replacement therapy in septic shock patients - local and national perspectives. Anaesthesia 2003; 58: 591-6
27. Millo J. Corticosteroids for patients with septic shock. JAMA 2003; 289: 41
28. Oxman AD, Guyatt GH. A consumer's guide to subgroup analysis. Ann Intern Med 1992; 116: 78-84
29. Bloomfield R, MacMillan M, Noble DW. Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003; 348: 2158
30. Beigel J, Eichacker P. Hydrocortisone and fludrocortisone improved 28-day survival in septic shock and adrenal insufficiency. ACP J Club 2003; 138: 44
31. Owen H, Spence AA. Etomidate. Br J Aanaesth 1984; 56: 555-7
32. Absalom A, Pledger D, Kong A. Adrenocortical function in critically ill patients 24 h after a single dose of etomidate. Anaesthesia 1999; 54: 861-7
33. Annane D, Sebille V, Bellisant E. Corticosteroids for patients with septic shock. JAMA 2003; 289: 43-4
34. Ledingham I, Watt I. Influence of sedation on mortality in critically ill multiple trauma patients. Lancet 1983; i: 1270
35. McKee JL, Finlay WEL. Cortisol replacement in severely stressed patients. Lancet 1983; i: 484
36. Ball C, Westhorpe R. Intravenous induction agents: etomidate. Anaesth Intens Care 2002; 30: 405
37. Annane D, Briegel J, Sprung CL. Corticosteroid insufficiency in acutely ill patients. N Engl J Med 2003; 348: 2157-8